|
|
|
|
|
|
|
Backward Thinking
|
|
Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Klöckner Pentaplast Launches Its 2020 Sustainability Report
London, UK – 19 July 2021 – Klöckner Pentaplast (kp or the
company), a global leader in high barrier protective packaging
solutions, today announced the release of its 2020 Sustainability
Report, detailing its progress and commitment to key sustainability
initiatives. The report provides details of performance relating to
topics that are material to its business and has been prepared in
accordance with the Global Reporting Initiative (GRI) Standards.
More info >> |
|
 |
White Papers |
 |
|
Challenges of Analytical Method Transfer in the Pharmaceutical Industry
RSSL
The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >> |
|
 |
Industry Events |
 |
Pharma Integrates 2021
16 November 2021, VIRTUAL CONFERENCE
Now in its tenth year, Pharma Integrates is a unique event bringing
together pharma and healthcare leaders across the Pharmaceutical
pipeline to address their needs, to share insights and create debate on
crucial topics that influence the future of patient outcomes.
More info >> |
|
|
|
